---
schema_version: "secwatch.filing_event.v1"
accession: "0001724521-24-000101"
form_type: "8-K"
ticker: "RCUS"
cik: "0001724521"
company_name: "Arcus Biosciences, Inc."
filed_at: "2024-06-06T23:59:59+00:00"
generated_at: "2026-06-01T05:57:02.399420+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.25
calibrated_materiality_score: 0.25
confidence: "high"
source: SEC EDGAR
---

# Arcus Biosciences adopts amended director compensation; annual meeting passes all proposals

## Summary
- New non-employee director compensation: $45,000 annual cash retainer; $25,000 extra for Lead Independent Director.
- Initial equity award: ~$750,000 grant-date value, 2/3 stock options and 1/3 RSUs, vesting over 3 years.
- Annual equity award: ~$400,000 grant-date value, vests fully in 12 months or until next annual meeting.
- Annual meeting results: all three Class III directors elected; Ernst & Young ratified; say-on-pay approved.

## SEC filing metadata
- accession: 0001724521-24-000101
- form_type: 8-K
- ticker: RCUS
- cik: 0001724521
- company_name: Arcus Biosciences, Inc.
- filed_at: 2024-06-06T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.25
- calibrated_materiality_score: 0.25
- confidence: high
- sec_items: 5.07, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1724521/000172452124000101/0001724521-24-000101-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1724521/000172452124000101/rcus-20240606.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001724521-24-000101
- JSON: https://secwatch.observer/filing/0001724521-24-000101.json
- Plain text: https://secwatch.observer/filing/0001724521-24-000101.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.